NCT01742052View on ClinicalTrials.gov

Dose-finding Study of MT-1303

PHASE2CompletedINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

October 31, 2014

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

MT-1303-Low

DRUG

MT-1303-Middle

DRUG

MT-1303-High

DRUG

Placebo

Trial Locations (18)

Unknown

Research Site, Brussels

Research Site, Sofia

Research Site, Edmonton

Research Site, Zagreb

Research Site, Prague

Research Site, Vantaa

Research Site, Berlin

Research Site, Budapest

Research Site, Roma

Research Site, Kaunas

Research Site, Katowice

Research Site, Moscow

Research Site, Belgrade

Research Site, Madrid

Research Site, Basel

Research Site, Kozyatagi, Istanbul

Research Site, Kiev

Research Site, London

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY